Methylation of Smad6 by protein arginine N-methyltransferase 1  by Inamitsu, Masako et al.
FEBS Letters 580 (2006) 6603–6611Methylation of Smad6 by protein arginine N-methyltransferase 1
Masako Inamitsua, Susumu Itoha,*, Ulf Hellmanb, Peter ten Dijkec, Mitsuyasu Katoa
a Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai,
Tsukuba, Ibaraki 305-8575, Japan
b Ludwig Institute for Cancer Research, Biomedical Center Box 595, Uppsala University, 751 24 Uppsala, Sweden
c Department of Molecular Cell Biology, Leiden University Medical Center, Postzone S-1-P, Postbus 9600, 2300 RC, Leiden, The Netherlands
Received 19 August 2006; revised 14 October 2006; accepted 8 November 2006
Available online 14 November 2006
Edited by Veli-Pekka LehtoAbstract Signal transduction pathways utilize posttranslational
modiﬁcations to regulate the activity of their components in a
temporal-spatial and eﬃcient fashion. Arginine methylation is
one of the posttranslational modiﬁcations that can result in
monomethylated-, asymmetric dimethylated- and/or symmetric
dimethylated-arginine residues in proteins. Here we demonstrate
that inhibitory-Smads (Smad6 and Smad7), but not receptor-
regulated- (R-)Smads and the common-partner Smad4, can be
methylated by protein arginine N-methyltransferase (PRMT)1.
Using mass-spectrometric analysis, we found that PRMT1 dime-
thylates arginine74 (Arg74) in mouse Smad6. PRMT1 interacts
with the N-terminal domain of Smad6 in which Arg74 residue
is located. Assays examined so far have shown no signiﬁcant dif-
ferences between the functions of Smad6 and those of methyla-
tion-defective Smad6 (Smad6R74A). Both wild-type and
Smad6R74A were equally eﬃcient in blocking BMP-induced
growth arrest upon their ectopic expression in HS-72 mouse B-
cell hybridoma cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Posttranslational modiﬁcation of proteins, such as phos-
phorylation, acetylation, glycosylation, ubiquitination and
SUMOylation, allows for structural and functional diversity,
and is a mechanism frequently used to regulate cellular signal-
ing events. Although methylation of arginine residues was dis-
covered more than 30 years ago [1], the functional signiﬁcance
of methylated arginine has been demonstrated only recently.
To date, nine protein arginine methyltransferases (PRMTs)
have been isolated and classiﬁed into two groups: type I and
type II enzymes [2,3]. While both types can catalyze x-NG-
monomethylation of arginine as an intermediate, type I en-
zymes (PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8)
promote asymmetric x-NG,NG-dimethylation of arginine resi-
due, whereas type II enzymes (PRMT5, PRMT7 and PRMT9)
catalyze the formation of symmetric x-NG,N 0G-dimethylargi-
nine. No enzymatic activity has been documented for PRMT2
in spite of its structural similarity to other PRMT family mem-
bers [2,3]. PRMT1-deﬁcient mice die at E6.5, whereas*Corresponding author. Fax: +81 29 853 3944.
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doi:10.1016/j.febslet.2006.11.008PRMT4-deﬁcient mice can survive till late embryogenesis or
perinatally. Thus, the lack of these PRMTs cannot be compen-
sated by other PRMTs [4,5]. Many of the proteins targeted by
PRMTs possess glycine–arginine rich (GAR) domains. In a
GAR domain, RGG, RG repeats or RXR are sequence motifs
used by PRMTs to methylate an arginine residue in proteins
[6]. Arginine methylation by PRMTs regulates subcellular
localization of proteins, enzymatic activities and protein–pro-
tein interactions [7]. The methylation status of Sam68 RNA
binding protein determines its subcellular localization [8]. Exo-
nuclease activity of MRE11 is abrogated by substitution of an
arginine residue regularly methylated by PRMT1 [9]. Further-
more, certain transcription factors or their co-activators can be
arginine-methylated by PRMTs, aﬀecting their transcriptional
activity [10–13].
Transforming growth factor-b (TGF-b) is a multi-functional
cytokine that regulates cell division, diﬀerentiation, migration,
adhesion, organization and death [14]. The TGF-b superfamily
is classiﬁed into three subfamilies: TGF-bs, activins, and bone
morphogenetic proteins (BMPs). Perturbation of TGF-b sig-
naling has been implicated in oncogenesis, ﬁbrosis, immune
disorders and vascular disorders [15]. Signaling of TGF-b fam-
ily members occurs via the formation of heteromeric com-
plexes of speciﬁc type I and type II serine/threonine kinase
receptors after ligand binding to receptors [16]. The type I
receptor, termed activin receptor-like kinase (ALK), is a direct
substrate for the constitutively active type II receptor kinase.
Ligand binding induces the assembly between type I and type
II receptors with ligand and promotes phosphorylation of the
GS domain in the type I receptor by active type II receptor ki-
nase, followed by activation of type I receptor kinase. Subse-
quently, active type I receptor kinase directly phosphorylates
receptor-regulated (R)-Smads, resulting in the propagation of
the signal in the cells. Phosphorylated R-Smads can make a
complex with the common-partner Smad (Co-Smad), Smad4,
to form ternary complexes, which accumulate in the nucleus,
where they regulate the transcription of target genes [17,18].
The inhibitory Smads (I-Smads), Smad6 and Smad7, form a
distinct subfamily of Smads that block TGF-b family signal-
ing. Smad6 preferentially antagonizes BMP signaling, whereas
Smad7 is a general inhibitor for TGF-b family signaling. I-
Smads stably associate with the activated type I receptor to
prevent R-Smads from being phosphorylated by type I recep-
tor kinase. Recently, it has been reported that I-Smads recruit
E3 ubiquitin ligases to the activated type I receptor and medi-
ate proteasome-dependent degradation of the type I receptor.
Consequently, TGF-b signaling is terminated [17]. In addition,
Smad7 recruits both GADD34 and the catalytic subunit ofblished by Elsevier B.V. All rights reserved.
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ing in promotion of dephosphorylation and inactivation of
the activated type I receptor [19]. Moreover, it is known that
Smad6 acts together with Hoxc-8, CtBP or HDACs as a tran-
scriptional co-repressor [20].
I-Smads have been found to receive posttranslational modi-
ﬁcations such as ubiquitination, acetylation and phosphoryla-
tion [21–23]. The balance of acetylation, deacetylation and
ubiquitination of lysine residues in Smad7 is critical for its sta-
bility [24]. It was recently reported that phosphorylation of
Smad6 by protein kinase X is required for diﬀerentiation of
HL-60 cells [25]. Of the Smad family, our study showed that
PRMT1 speciﬁcally methylates I-Smads. Moreover, we identi-
ﬁed the methylated arginine residue in Smad6.2. Materials and methods
2.1. Expression plasmids
Mouse Smad6R74A mutant was made using a QuickChange site-di-
rected mutagenesis kit (Stratagene) with pcDNA3-Flag-mouse Smad6
[26] as the template. Constitutively active ALK6 (ALK6ca)/V5 was
constructed by ligation of the insert from pcDNA3-ALK6ca/HA [27]
with pcDNA3.1-V5-His-A (Invitrogen). Subsequently, the insert was
ligated into the pcDEF3 vector again [28]. GST-PRMT1, GST-
PRMT4, GST-PRMT5, GST-PRMT6, GST-GAR, HA-PRMT1,
Flag-Smurf1ca and Myc-CtBP were kindly provided by Drs. Stallcup,
Bedford, Pestka, Imamura and Feng [29–33]. The constructs for
pcDNA3-Flag-Smad6, pcDNA3-Flag-Smad6N, pcDNA3-Flag-Smad-
6C, pcDNA3-Myc-Smad6, pcDNA3-Flag-Smad7, GST-Smad3, GST-
Smad4 and (SBE)4-luc have previously been described [27,34–38].
pGEX-4T-1 (GST alone) and CH110 for normalization of luciferase
activity were purchased from Amersham Biosciences. GST-Smad5,
GST-Smad6, GST-Smad6R74A, GST-Smad6(R15A,R17A), GST-
Smad6(R74A,R82A), GST-Smad6R383A and GST-Smad7 were gen-
erated using pGEX-4T-1.
2.2. Cell culture and transfections
COS7, HepG2 and HS-72 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM, Sigma) containing 10% fetal calf serum
(FCS, Bio-west) and 1·MEM non-essential amino acids (NEAA)
(Sigma). For selection of stable transformants with pcDNA3-Flag-
Smad6R74A in HS-72 cells, the cells were cultured in the presence of
500 lg/ml G418 (Gibco). All media included penicillin and streptomy-
cin as antibiotics. The HS-72 transformant expressing Flag-Smad6,
termed Sma6A, was obtained from Dr. Ishisaki [39].
2.3. Immunoprecipitation and Western blotting
To detect methylated Smads, indicated plasmids were transfected in
COS7 cells at 5 · 105 cells/6 cm-dish using FuGENE 6 (Roche). Forty
hours after transfection, the cells were lysed in 0.5 ml of TNE buﬀer
(10 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% NP-40,
1 mM PMSF, 5 lg/ml leupeptin, 100 U/ml aprotinin, 2 mM sodium
vanadate, 40 mM NaF and 20 mM b-glycerophosphate). After being
precleared with protein G-Sepharose beads (Amersham Biosciences)
for 30 min at 4 C, the cell lysates were incubated with anti-Flag M5
antibody (Sigma) for 2 h at 4 C. Subsequently, protein G-Sepharose
beads were added to the reaction mixture and incubated for 30 min
at 4 C. After the immunoprecipitates were washed three times with
TNE buﬀer, the proteins in the immunoprecipitates and the aliquots
of total cell lysates were separated by SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE) and transferred to a Hybond-C Extra mem-
brane (Amersham Biosciences). The membrane was subsequently
probed with anti-monomethyl- and dimethyl-arginine antibody (Ab-
cam). Primary antibodies were detected with horseradish peroxidase-
conjugated goat anti-mouse antibody (Amersham Biosciences) and
chemiluminescent substrate (Pierce). The expression of proteins in to-
tal cell lysates was detected by Western blotting using anti-Flag M5 or
anti-HA12CA5 (Roche) antibody. The detection of the interactions be-
tween Flag-Smad6 and HA-PRMT1 was performed by immunoprecip-
itation followed by Western blotting according to the above methodexcept that anti-HA antibody was used in immunoprecipitation and
anti-Flag M5 antibody was used in Western blotting.
2.4. In vitro methylation assay
All of the GST fusion proteins were puriﬁed using GSH-Sepharose
4B (Amersham Biosciences). GST-Smads (5 lg) were reacted with 2 lg
of GST-PRMT1 plus 4 ll of S-adenosyl-L-[methyl-3H] methionine
([3H]AdoMet; 37 MBq/ml, Amersham Biosciences) in 50 ll of PBS
for 90 min at 37 C. Subsequently, samples were loaded on 7.5%
SDS–PAGE and stained with 0.05% Coomassie Brilliant Blue R-250
(CBB), followed by detection of [3H]-labeled proteins using BAS2500
(Fuji ﬁlm).
2.5. MALDI-ToF MS analysis
GST-Smad6 or GST-Smad6R74A was incubated with GST-PRMT1
and 1.67 mM AdoMet in PBS for 90 min at 37 C. Each sample was
mixed with 2· sample buﬀer (4% SDS, 20 mM dithiothreitol, 20% glyc-
erol, 125 mM Tris and 0.002% bromophenol blue) and boiled at 98 C
for 10 min, and then reacted with 20 mM iodoacetamide at 25 C for
20 min in a dark room. Samples were then applied on 7.5% SDS–
PAGE and stained with CBB. Corresponding bands for GST-Smad6
or its mutant were excised from the gel and treated for in-gel trypsin
digestion as previously described [40]. Brieﬂy, the gel bands were
washed with acetonitrile and ammonium bicarbonate. After CBB
was de-stained, the gels were dried with neat acetonitrile. A solution
of modiﬁed sequence grade porcine trypsin (Promega) was added
and allowed to soak into the gel pieces on ice. After incubation over-
night at 30 C and acidiﬁcation, the digests were analyzed for mass
ﬁngerprinting by matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-ToF MS) on a Bruker Ultraﬂex
TOF/TOF (Bruker Daltonics, Bremen, Germany). The instrument
settings were those optimized for analytes up to about 4000 Da, and
the matrix used was a-cyano 4-hydroxy-cinnamic acid. The search
for peptides representing methylated arginine residues was performed
using GPMAW (Lighthouse Data, Odense, Denmark). The sequence
coverage for GST-Smad6 in the presence of PRMT1 was 39%, while
that for GST-Smad6 alone was 42%.
2.6. Detection of phosphorylated Smad5
HS-72 stable transformants were cultured without FCS 12 h before
stimulation with 500 ng/ml BMP-6, which was kindly provided by Dr.
Sampath. One hour after stimulation with BMP-6, the cells were lysed
and loaded on 8% SDS–PAGE. Anti-phosphorylated Smad1/5 (pS1)
[41], anti-Smad5 [42] and anti-Flag M5 antibodies were used as pri-
mary antibodies. The detection method was the same as that described
above.
2.7. MTT assay
To observe the growth inhibition of HS-72 stable transformants by
BMP-6, MTT assay was performed [43].3. Results
3.1. Methylation of I-Smads by PRMT1
The PRMT family can catalyze arginine methylation of a
number of transcriptional factors [7]. To examine if Smads
are substrates for the PRMT family, we examined whether
GST-Smads can be methylated by GST-PRMTs in vitro. As
seen in Fig. 1a, GST-Smad6 and GST-Smad7 were eﬃciently
methylated by GST-PRMT1, whereas GST-Smad3 and GST-
Smad5 (termed TGF-b/activin and BMP R-Smads, respec-
tively), as well as GST-Smad4 and GST alone were not, or
only very weakly (Fig. 1a and c). In addition, GST-PRMT4,
GST-PRMT5 and GST-PRMT6 did not catalyze methylation
of GST-Smads (data not shown). To conﬁrm that PRMT1 can
catalyze methylation of I-Smads in vivo, we transfected
I-Smads with or without PRMT1 in COS7 cells. Then, methyl-
ated I-Smads after immunoprecipitation using Flag antibody
were detected with anti-methylarginine antibody. Both Smad6
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Fig. 1. I-Smads are substrates for PRMT1. (a, b) In vitro methylation of Smad proteins by PRMT1. GST-PRMT1 was incubated with GST-Smad3,
GST-Smad4, GST-Smad6, GST-Smad7 or GST alone in the presence of [3H]AdoMet as a methyl donor. GST-GAR was used as a positive control
for methyltransferase activity. (a) [3H]-labeled proteins visualized by autoradiography and (b) total proteins visualized by Coomassie blue staining.
(c) Smad5 is not methylated by PRMT1. GST-PRMT1 was incubated with GST-Smad5 or GST-Smad6 in the presence of [3H]AdoMet. Proteins
were visualized by autoradiography (upper panel) or Coomassie blue staining (lower panel). (d) PRMT1 catalyzes methylation of I-Smads in COS7
cells. Flag-Smad6 and Flag-Smad7 were transfected in COS7 cells with or without HA-PRMT1. To detect methylated Smads, cell lysates were
immunoprecipitated with anti-Flag M5 antibody, followed by Western blotting with anti-methyl-arginine antibody (upper and second panels).
Although the intensity of the band corresponding to methylated Smad6 was very weak, the membrane shown in the upper panel was exposed for a
longer time than that shown in the second panel. Using total cell lysates, expression controls for Smads (third panel) and PRMT1 (lower panel) were
shown by anti-Flag M5 and anti-HA12CA5 antibodies, respectively. (e) Methylation of Smad6 decreases upon ALK6 activation in COS7 cells. Flag-
Smad6 was transfected in COS7 cells in combination with HA-PRMT1 and ALK6ca/V5. To detect methylated Smad6, cell lysates were
immunoprecipitated with anti-Flag M5 antibody, followed by Western blotting with anti-methyl-arginine antibody (upper panel). Using total cell
lysates, expression controls for Smad6 (second panel), PRMT1 (third panel) and ALK6 (lower panel) were shown by anti-Flag M5, anti-HA12CA5
and anti-V5 antibodies, respectively.
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although the level of methylation in Smad7 was higher than
that in Smad6 (Fig. 1d). Next, we examined if stimulation of
cells with BMP inﬂuences methylation of Smad6 by PRMT1.
As seen in Fig. 1e, a constitutively active BMP type I receptor
termed ALK6ca, which transduces BMP signaling without
ligand stimulation, signiﬁcantly reduced PRMT1-mediated
Smad6 methylation.
3.2. Identiﬁcation of methylated arginine residue in Smad6
To identify methylated arginine residue(s) in I-Smads, we
analyzed trypsinized peptides from I-Smads whose methylation
was catalyzed by PRMT1 in vitro using MALDI-ToF MS. We
identiﬁed ﬁve possible candidates for a methylated arginine res-
idue in Smad6. Due to the high background, we could not suc-ceed in identifying methylated arginine residues in Smad7 (data
not shown). Thus, we focused on methylation of Smad6 in the
subsequent experiments. As an initial step, ﬁve arginine resi-
dues that are possibly methylated by PRMT1 were substituted
with alanine residues. We then investigated in vitromethylation
of each GST-Smad6 mutant by GST-PRMT1. Of the GST-
Smad6 mutants, GST-Smad6(R74A,R82A) was not methyl-
ated (Fig. 2a). Subsequently, we found that substitution of
Arg74 to Ala in Smad6 blocks methylation of Smad6 by
PRMT1 (Fig. 2b and c). It has been reported that PRMT1
can asymmetrically dimethylate and/or monomethylate an argi-
nine residue in proteins [7]. To further conﬁrm how Arg74 in
Smad6 is modiﬁed by PRMT1, MALDI-ToF MS analysis
was performed using GST-Smad6 or GST-Smad6R74A in the
absence or presence of GST-PRMT1. By comparing the mass
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Fig. 2. Arg74 in mouse Smad6 is a target for methylation by PRMT1. (a) Methylation of Smad6 (R74A,R82A) by PRMT1 is drastically decreased
in vitro. GST-PRMT1 was incubated with GST-Smad6 or its mutants in the presence of [3H]AdoMet. Proteins were visualized by autoradiography
(upper panel) or Coomassie blue staining (lower panel). (b) PRMT1-methylated arginine residue in mouse Smad6. The position of the methylated
arginine in Smad6 is indicated in bold. The grey box indicates the MH2 domain. (c) Smad6R74A is not methylated by PRMT1 in vitro. GST-PRMT1
was incubated with GST-Smad6 or GST-Smad6R74A in the presence of [3H]AdoMet. Proteins were visualized by autoradiography (upper panel) or
Coomassie blue staining (lower panel). (d) Analysis of methylated peptides in Smad6 by MALDI-ToF-MS. GST-Smad6 or GST-Smad6R74A was
incubated with AdoMet in vitro in the absence or presence of GST-PRMT1. The proteins were resolved by SDS–PAGE and then stained with
Coomassie blue. Each apparent band at 65 kDa was excised, in-gel digested with trypsin, and analyzed by MALDI-ToF-MS. The arrow indicated the
peak corresponding to the peptide including a dimethylarginine residue. (e) Smad6R74A is not methylated in COS7 cells. Flag-Smad6 or Flag-
Smad6R74A was transfected in COS7 cells in the absence or presence of HA-PRMT1. To detect methylated Smad6, cell lysates were
immunoprecipitated with anti-Flag M5 antibody, followed by Western blotting with anti-methyl-arginine antibody (upper panel). Using total cell
lysates, expression controls for Smad6 (middle panel) and PRMT1 (lower panel) were shown with anti-Flag M5 and anti-HA12CA5 antibodies,
respectively.
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sample, which has a unique mass of 1238.67 Da, representing
the peptide DAVGPR(2Me) GAAIAGR. The corresponding
peptide in the mutated variant DAVGPAGAAIAGRwas dem-
onstrated by the mass 1125.60, and this peak was not aﬀected
by incubation with GST-PRMT1. Obviously, this mass was
not found in the methylated protein. Thus, our data showed
that Arg74 in Smad6 was dimethylated in vitro (Fig. 2d). To par-
allel the in vitro methylation assay, COS7 cells were transfected
with Flag-Smad6 or Flag-Smad6R74A with or without HA-
PRMT1. Subsequently, methylated Smad6 was detected with
an anti-methyl-arginine antibody. Fig. 2e shows that Smad6,
but not Smad6R74A, was methylated by PRMT1, indicating
that Arg74 in Smad6 is a predominant site for methylation both
in vivo and in vitro. However, it is possible that substitution of
Arg74 to Ala in Smad6 aﬀects the ternary structure of Smad6 to
interfere access of PRMT1 to other arginine residue(s) in
Smad6 or methylation of Arg74 is required for methylation of
other arginine residue(s) in Smad6. Currently, therefore, the
presence of one or more additional methylation sites in Smad6
cannot be ruled out.
3.3. Interaction of Smad6 with PRMT1
Since PRMT1 methylates Smad6, both proteins should
interact with each other. To examine this possibility, Smad6or Smad6R74A was transfected in COS7 cells with HA-
PRMT1 in the absence or presence of ALK6ca. As seen in
Fig. 3a, PRMT1 could associate with Smad6 as well as
Smad6R74A, although the binding between PRMT1 and
Smad6 was marginally stronger than that between PRMT1
and Smad6R74A. In addition, ALK6ca had no signiﬁcant
eﬀect on the interaction between Smad6 and PRMT1. To
determine the region of Smad6 that interacts with PRMT1,
Flag-tagged Smad6N and Flag-tagged Smad6C were transfec-
ted with HA-tagged PRMT1 in COS7 cells, and this was
followed by immunoprecipitation with Flag antibody and
Western blotting with HA antibody. Fig. 3b shows that Smad6
lacking the MH2 domain, Smad6N, binds to PRMT1, but
Smad6C does not.
3.4. Functional diﬀerences between Smad6 and Smad6R74A
Smad6 is known to inhibit BMP signaling (26, 39). To exam-
ine if, like Smad6, Smad6R74A has an ability to inhibit BMP
signaling, (SBE)4-luc, whose activity is induced by BMP (38),
was co-transfected with Smad6 or Smad6R74A in HepG2
cells. Then, the cells were stimulated with BMP. As seen in
Fig. 4a, not only Smad6R74A but also Smad6 can eﬃciently
block BMP-induced luciferase activity in a dose-dependent
manner. We also tried to explore interaction of Smad6R74A
with ALK6ca (26), Smurf1 (32) or CtBP (33) because Smad6
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Fig. 2 (continued)
M. Inamitsu et al. / FEBS Letters 580 (2006) 6603–6611 6607mediates its eﬀect via interaction with these proteins. However,
we could not observe any diﬀerences between Smad6 and
Smad6R74A on interaction with ALK6ca, Smurf1 or CtBP
although both the wild-type and mutant Smad6 could interact
with them (Fig. 4b–d).
Since Smad6 inhibits BMP-induced growth inhibition and
apoptosis of HS-72 mouse B-cell hybridoma cells [39], we exam-
ined the eﬀect of ectopic expression of Smad6R74A or wild-type
Smad6 on BMP-induced response. A Flag-Smad6R74A expres-
sion vector with a G418-resistant marker was stably transfected
into HS-72 cells, and two transformants, Smad6R74A-17 and
Smad6R74A-22, that express Smad6R74A at a high level wereobtained (data not shown). In the subsequent experiments, the
properties of these two clones were compared with those of
Sma6A expressing wild-type Smad6 [39]. Using a speciﬁc anti-
body for phosphorylated BMP R-Smad (termed pS1), we ﬁrst
compared the phosphorylation of endogenous BMP R-Smads
induced by BMP between parental HS-72 cells and transfor-
mants for Smad6 or its mutants. Phosphorylation of BMP
R-Smads by BMP was almost abolished by both Smad6 and
its mutants (Fig. 5a). To examine if Smad6 mutants aﬀect
BMP-induced growth arrest in HS-72 cells, we carried out
MTT assay using Sma6A, Smad6R74A-17 and Smad6-
R74A-22. Consistent with the inhibition of BMP R-Smad
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blocked in both the Smad6R74A-expressing cells and Sma6A
(Fig. 5b).4. Discussion
Posttranslational modiﬁcation plays a prominent role in the
regulation of Smad activity. Although phosphorylation, acety-
lation, glycosylation, ubiquitination and SUMOylation have
been demonstrated in Smad proteins [17], here we report for
the ﬁrst time methylation of arginine residue(s) in Smads.
Our results showed that I-Smads, Smad6 and Smad7, were
methylated by PRMT1 in vitro and in vivo. Speciﬁcity is shown
by the fact that R-Smads and Smad4 are not methylated on
arginine residues, and that PRMT4, PRMT5 and PRMT6
show no signiﬁcant activity for Smad targets. Arginine tar-
geted by PRMT1, consisting of the RG motif, is conserved
between human and mouse Smad6s (Arg75 for human Smad6,
Arg74 for mouse Smad6), as well as between mouse Smad6 and
Smad7 (Arg38 for mouse and human Smad7s). In the present
study, we could not identify any methylated arginine residue
in Smad7 that was dependent on the PRMT1 treatment. We
are investigating the possibility that the conserved arginineresidue in Smad7 is methylated by PRMT. The interaction
between PRMT1 and Smad6 was demonstrated with the
co-immunoprecipitation assay. Since the N-terminal part of
Smad6 interacts with PRMT1, the region around Arg74 residue
might be important for Smad6 to interact with PRMT1.
Both wild-type and methylation-defective mutant Smad6R74A
were equally eﬃcient in blocking BMP-induced growth
inhibition upon their ectopic expression in HS-72 mouse
hybridoma cells. Smad6 is known to mediate its eﬀects via
interaction with other proteins [20,23,26,32,33,43–46]. How-
ever, comparison of the interaction of wild-type Smad6 and
its methylation-defective mutant with the activated BMP type
I receptors, Smurfs, arkadia, phosphorylated Smad1, TAK1,
TAB1, CtBP, AMSH and HDAC1 revealed no signiﬁcant diﬀ-
erences (Fig. 4 and data not shown). We are currently investi-
gating the functional signiﬁcance of methylation using more
unbiased approaches such as transcriptional proﬁling of
cells that ectopically express Smad6R74A mutant or wild-type
Smad6.
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